Sponsor
Disruptive Pharma AB
Uppsala Science Park, 751 83 Uppsala, Sweden
About the sponsor
Disruptive Pharma AB is active in oncology, with research linked to hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma. Its clinical interests are centered on solid tumours where targeted therapies are clinically relevant.
- Hepatocellular carcinoma
- Renal cell carcinoma
- Differentiated thyroid carcinoma
The sponsor’s trial portfolio reflects a focus on cancer treatment areas where tyrosine kinase inhibitor therapies are commonly used.
Try clearing a filter, or search the whole catalogue.
Are you running a clinical trial?
Increase visibility for your trials and help patients find your site through our platform.